Anda

What Anda does

Anda is a US-based wholesale pharmaceutical distributor operating as an affiliate of Teva Pharmaceuticals USA, headquartered in Weston with 251–500 employees and a history dating to 1992. The company runs the AndaNet B2B e-commerce platform, through which pharmacies, hospitals, and health plans order generic and biosimilar pharmaceuticals; the platform features DSCSA-compliant supply chain traceability, Azure AD single sign-on, Salesforce Identity Hub integration, and standard order management functionality. Anda's flagship strategic product is an FDA-designated interchangeable biosimilar to Humira (adalimumab), priced at 95% below brand-name cost and scheduled for nationwide distribution effective July 1, 2026 via wholesale partner Birdi Inc. and PBM intermediary MedImpact Holdings.

The company's revenue model is transaction-based unit pricing on pharmaceutical distribution, paired with a deliberate structural deviation from incumbent rebate economics — Anda eliminates rebates and provides upfront discounts to increase price transparency for buyers. The customer base is segmented across healthcare providers (hospitals, health plans) and pharmacies nationwide, with vertical segmentation. Anda does not market directly to consumers; all commercial activity flows through B2B channels. Distribution is multi-channel: direct enterprise ordering via AndaNet combined with channel-partner reach through Birdi (wholesale) and MedImpact (commercial intermediary) to access payer-controlled demand. Regulatory positioning — specifically the FDA interchangeable designation — is the central enabler of Anda's commercial model, as it permits pharmacy-level substitution without prescriber intervention, materially lowering adoption friction relative to non-interchangeable biosimilars.

Name

Anda

Legal name

Anda

Website

https://andanet.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

251–500 employees

Short description

Anda is a US wholesale pharmaceutical distributor and Teva Pharmaceuticals USA affiliate that distributes generics and biosimilars via the AndaNet B2B platform to hospitals, pharmacies, and health plans, including an FDA-designated interchangeable Humira biosimilar at 95% below brand cost.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

akta.pro secondary industry

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD)

Keywords

• Pharmaceutical distribution
• Generic pharmaceuticals
• Biosimilar manufacturing
• Pharmaceutical supply chain
• B2B drug distribution

Headquarters

HQ city

Weston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Distribution: ANDA distributes generic and biosimilar pharmaceuticals to healthcare providers (hospitals, pharmacies, health plans). Revenue is generated through product sales at transparent, upfront pricing without rebates.
2. Biosimilar Manufacturing: ANDA manufactures pharmaceutical products (biosimilars) as an affiliate of Teva Pharmaceuticals USA. Products are distributed through channel partners like MedImpact and Birdi Inc.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Anda is a wholesale distributor of pharmaceutical products in the United States, operating as an affiliate of Teva Pharmaceuticals USA. It distributes generic and biosimilar pharmaceuticals through its AndaNet B2B e-commerce platform to hospitals, pharmacies, and health plans nationwide, and manufactures an FDA-designated interchangeable biosimilar to Humira (adalimumab) priced 95% below brand-name cost. Products are made available through direct B2B ordering as well as channel partners Birdi Inc. and MedImpact.

Product overview

Anda operates a pharmaceutical distribution platform (AndaNet) for generic and branded pharmaceuticals, including biosimilar products manufactured by Anda as an affiliate of Teva Pharmaceuticals USA. The platform enables pharmacies, hospitals, and plans to order pharmaceutical products, track deliveries, manage returns, and access pricing through a web-based catalog system.

Differentiator

Problem solved

Functional benefit

Products and services

• AndaNet Web-based B2B e-commerce platform enabling pharmacies, hospitals, and health plans to browse the pharmaceutical catalog, view pricing, place orders, manage accounts, and track deliveries. Includes cart, checkout, order history, returns, DSCSA compliance features, and Azure AD single sign-on for enterprise customers.
• Unbranded Humira Biosimilar (adalimumab) FDA-designated interchangeable biosimilar to Humira (adalimumab) manufactured by Anda as an affiliate of Teva Pharmaceuticals USA. The interchangeable designation enables pharmacy-level substitution without prescriber intervention. Distributed through Birdi Inc. with MedImpact as commercial intermediary; priced at 95% below brand-name cost with transparent, rebate-free upfront pricing.

Quantifiable outcome

• 95% cost reduction compared to brand-name Humira

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• MedImpact Holdings, Inc.coreChannel Partner/ Reseller/ Distributor · 11 February 2026MedImpact serves as the commercial intermediary for Anda's unbranded Humira biosimilar launch. MedImpact announced the product launch on February 11, 2026, pricing the product at 95% below brand-name cost. The partnership enables distribution to any hospital, plan, or pharmacy nationwide.
• Birdi Inc.coreChannel Partner/ Reseller/ Distributor · 11 February 2026Birdi Inc. serves as the distribution channel for Anda's biosimilar product, enabling physical distribution to pharmacies and hospitals nationwide. The product launch is scheduled for July 1, 2026.
• Teva Pharmaceuticals USAcoreOEM/ Whitelabel/ Licensing PartnerAnda is explicitly identified as an affiliate of Teva Pharmaceuticals USA. This affiliate relationship provides Anda with pharmaceutical manufacturing capabilities, FDA regulatory pathway access, and the ability to produce FDA-designated interchangeable biosimilars.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Coherus BioSciences: A U.S. biosimilar-focused biopharmaceutical company that markets interchangeable biosimilars including Udenyca. Comparable to Anda in pursuing the interchangeable biosimilar opportunity and targeting payer/pharmacy channels for substitution economics.
• ClarusONE Sourcing Services: A Walmart/McKesson joint venture focused on sourcing and distributing generic and biosimilar pharmaceuticals. Comparable to Anda in channeling interchangeable and biosimilar products to large pharmacy networks with transparent, rebate-light pricing.
• Amneal Pharmaceuticals: A U.S. generics and biosimilar manufacturer with interchangeable biosimilar products (including adalimumab). Comparable to Anda in combining manufacturing capability with biosimilar distribution and pricing disruption themes in the U.S. market.
• Alvotech: A biosimilar manufacturer developing interchangeable adalimumab and other biosimilars for the U.S. market. Directly comparable to Anda as a competing interchangeable Humira biosimilar entrant leveraging FDA interchangeability designation.
• Organon & Co. A global women's health and biosimilars-focused pharma company spun off from Merck. Comparable to Anda in pursuing U.S. biosimilar commercialization and competing for payer and pharmacy share against brand-name biologics.

Direct peers

• Smith Drug Company: A regional U.S. pharmaceutical wholesaler distributing generics, brands, and specialty products to independent and retail pharmacies. Operates a similar distribution model to Anda's AndaNet platform and serves overlapping pharmacy customer segments.
• Morris & Dickson: One of the largest independent U.S. pharmaceutical wholesalers, serving retail pharmacies, hospitals, and health systems. Comparable to Anda as a mid-sized full-line distributor competing against the Big 3 with similar product breadth and customer types.
• Cencora (formerly AmerisourceBergen): One of the Big 3 U.S. pharmaceutical wholesalers, distributing generics, biosimilars, and specialty pharmaceuticals to pharmacies, hospitals, and health systems. Cencora's scale and biosimilar distribution programs make it a direct competitor to Anda's distribution economics and payer reach.
• McKesson Corporation: The largest U.S. pharmaceutical wholesaler and Anda's most direct comparator. McKesson distributes branded, generic, and biosimilar pharmaceuticals to hospitals, pharmacies, and health systems nationwide — overlapping with Anda's AndaNet B2B distribution model and customer base.
• Cardinal Health: The third of the Big 3 U.S. pharmaceutical wholesalers, distributing generics, biosimilars, and specialty products to retail pharmacies, hospitals, and integrated delivery networks. Comparable to Anda in distribution channels, customer mix, and biosimilar program offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anda